首页> Future oncology (London, England)> Cemiplimab in the treatment of metastatic basal cell carcinoma.

Cemiplimab in the treatment of metastatic basal cell carcinoma.

导出 LinkOut

翻译打印收藏纠错

第一作者： Monika,Bapna

第一单位： Department of Dermatology, Georgetown University School of Medicine, Washington, DC, USA.

作者： Monika,Bapna ^[1] ; Emily,Ruiz ^[2]

作者单位： Department of Dermatology, Georgetown University School of Medicine, Washington, DC, USA. ^[1] Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. ^[2]

关键词 Metastatic basal cell carcinoma (mBCC)PD-1 inhibitor advanced basal cell carcinoma cemiplimab checkpoint inhibitors in oncology hedgehog inhibitor resistance immunotherapy for skin cancer real-world evidence in immunotherapy

DOI 10.1080/14796694.2025.2511568

PMID 40432222

发布时间 2025-05-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Future oncology (London, England)

1-7页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Future oncology (London, England)

1-7页

检索历史清除

Cemiplimab in the treatment of metastatic basal cell carcinoma.

Future oncology (London, England)

相似文献

同项目论文

Future oncology (London, England)

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Cemiplimab in the treatment of metastatic basal cell carcinoma.

Future oncology (London, England)

相似文献

同项目论文

Future oncology (London, England)

相关期刊

检索历史清除